title: Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
abstract: OBJECTIVE
  Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib.
  
  
  METHODS
  Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as first-line treatment and subsequent salvage treatment with erlotinib.
  
  
  RESULTS
  A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs.
  
  
  CONCLUSIONS
  For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib.
authors.affiliation: Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
authors.forename: Matthew K
authors.initials: MK
authors.lastname: Wong
authors.forename: Alvis I
authors.initials: AI
authors.lastname: Lo
authors.forename: Bing
authors.initials: B
authors.lastname: Lam
authors.forename: W K
authors.initials: WK
authors.lastname: Lam
authors.forename: Mary S
authors.initials: MS
authors.lastname: Ip
authors.forename: James C
authors.initials: JC
authors.lastname: Ho
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D016879:Salvage Therapy / Q000379:methods*; D017211:Treatment Failure
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references.pmid: 17020982
references.citation: Jpn J Clin Oncol. 2006 Aug;36(8):523-6
references.pmid: 16803841
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7738-40
references.pmid: 16234533
references.citation: J Thorac Oncol. 2007 Aug;2(8):758-61
references.pmid: 17762344
references.citation: Clin Cancer Res. 2007 Jun 15;13(12):3731-7
references.pmid: 17575239
references.citation: Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37
references.pmid: 16257339
references.citation: J Thorac Oncol. 2008 Apr;3(4):400-4
references.pmid: 18379359
references.citation: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references.pmid: 16514137
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2528-33
references.pmid: 17577030
references.citation: PLoS Med. 2005 Mar;2(3):e73
references.pmid: 15737014
references.citation: Lung Cancer. 2009 Aug;65(2):204-7
references.pmid: 19110337
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):7060-7
references.pmid: 18981003
references.citation: Clin Oncol (R Coll Radiol). 2006 Oct;18(8):637-9
references.pmid: 17051957
references.citation: BMC Cancer. 2007 Mar 20;7:51
references.pmid: 17374153
references.citation: JAMA. 2003 Oct 22;290(16):2149-58
references.pmid: 14570950
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2445-59
references.pmid: 15753456
references.citation: J Clin Oncol. 2003 Jun 15;21(12):2237-46
references.pmid: 12748244
references.citation: Ann Oncol. 2008 Dec;19(12):2039-42
references.pmid: 18644828
references.citation: PLoS Med. 2005 Jan;2(1):e17
references.pmid: 15696205
references.citation: J Clin Oncol. 2006 Jan 1;24(1):64-9
references.pmid: 16382114
references.citation: Nat Rev Cancer. 2007 Mar;7(3):169-81
references.pmid: 17318210
references.citation: Lung Cancer. 2007 Dec;58(3):414-7
references.pmid: 17618013
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):3032-7
references.pmid: 15837758
references.citation: N Engl J Med. 2005 Feb 24;352(8):786-92
references.pmid: 15728811
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Lung Cancer. 2005 Dec;50(3):417-8
references.pmid: 16129510
references.citation: J Thorac Oncol. 2008 Aug;3(8):912-4
references.pmid: 18670311
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3831-7
references.pmid: 16921034
references.citation: BMJ. 1995 Oct 7;311(7010):899-909
references.pmid: 7580546